CRISPR Therapeutics
Manufacturing · Switzerland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Baarerstrasse 14, Zug, Zug, 6300, Switze...Phone Number
+41 415613277Website
www.crisprtx.comRevenue
$11 MillionStock Symbol
CRSPIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About CRISPR Therapeutics
Crispr Therapeutics, founded in 2013 and headquartered in Zug, Switzerland, is a developer of gene-based medications that target diseases at the molecular level.Explore more
CRISPR Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CRISPR Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if CRISPR Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at CRISPR Therapeutics
Check if CRISPR Therapeutics has recently received funding, and reach out quickly before it becomes old news!
CRISPR Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if CRISPR Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on CRISPR Therapeutics recently announced quarterly report
Product Launch: Get notified when CRISPR Therapeutics launches new products
Funding: Get notified immidiatlly once CRISPR Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at CRISPR Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
CRISPR Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CRISPR Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CRISPR Therapeutics.
CRISPR Therapeutics financials insights
Gather financial insights about CRISPR Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Stock Offering
$56M
CRISPR Therapeutics Tech Stack
A closer look at the technologies used by CRISPR Therapeutics
See more technologies
Most Recent Scoops
Hiring Plans
CRISPR Therapeutics has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Project
CRISPR Therapeutics is advancing CTX611, a long-acting siRNA administered once every six months that targets factor XI as a blood thinner with reduced bleeding risk, with encouraging Phase 1 data reported and Phase 2 data in a total knee arthroplasty setting expected by end of this year. The program is expected to be Phase 3-ready by end of year or early next year.
Project
CRISPR Therapeutics has identified severe hypertriglyceridemia as the most likely Phase 3 indication for CTX310, citing limited existing treatment options and the appeal of a one-and-done therapy, with Phase 3 design to be informed by Phase 1B data and regulatory feedback expected by end of year.
Project
CRISPR Therapeutics News & Media
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
The next six months may be decisive for the biotech.Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CRISPR Therapeutics
Sign Up For FreeTo access detailed company insights
Crispr Therapeutics, founded in 2013 and headquartered in Zug, Switzerland, is a developer of gene-based medications that target diseases at the molecular level.... Read More
